Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Slides:

Advertisements

Similar presentations

Telehomecare: Outcomes and Patient Experiences

Advertisements

SOLVD (Studies of Left Ventricular Dysfunction)

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.

 Presented by Kara Derry, Oksana Marchenko, Sonja Wrobewski, and Carolyn Zielinski.

2016 Annual Data Report, Vol 2, ESRD, Ch 5

Association between Systolic Blood Pressure

Prior Trials of RAAS Inhibitors

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.

EMPHASIS-HF Extended Follow-up

Hospitalizations and Healthcare Costs Need for Reduction in Hospitalizations of Patients With HF

Medi-Cal Medically Tailored Meals Pilot Program

Acute Heart Failure.

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

Cardiac Biomarkers.

Biomarkers in Heart Failure

Select Topics in Cardiovascular Medicine

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Cost Effectiveness and Optimal Outcomes in HF

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Heart Failure Management Coordinated Care Approaches

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Heart Failure Prevention: Mission Impossible?

Treating Vasodilatory Shock in the ICU

Treating HFrEF: Challenges Faced

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Preventing Heart Failure Readmission and Progression

Biomarker-Guided HF Therapy: Is It Cost-Effective?

Tackling CV Risk in T2DM.

The Heart Failure Team Heart Failure Care Map First 24 hours.

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

LEADER One Year On.

Using Heart Rate as a Biomarker in Clinical Practice.

Multidisciplinary Management of Hyperkalemia:

Overcoming Clinical Inertia

Case #1 Case #1 (cont) Case #1 (cont)

Learning Objectives CMS Measures in HF: 30-day Hospital Readmission Rates.

Updates in Heart Failure:

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

New Strategies to Reduce HF Readmissions

Impedence-guided management

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Iron Deficiency in Heart Failure

Improving Adherence to Antiplatelet Therapy After an ACS Event

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

Baseline Characteristics by Baseline N-BNP Level

Peter E. Carson et al. JCHF 2015;3:

Contemporary Considerations in Biomarker-Guided Therapy

HF-Related Hospitalization and Readmissions

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

AHF Epidemiology Readmissions Reduction Program.

Pulmonary Arterial Hypertension and Hospitalizations

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

What's New in Oral Combination Therapy for Type 2 Diabetes?

Cohort and Community Surveillance Components

My PAH Patient.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Heart Failure Epidemiology (US Data)

CHF Hospitalizations by Age, 2000 and 2010

Consequences of Heart Failure

Impact of Affordable Care Act on HF Readmission

Impact of Affordable Care Act on HF Readmission (cont)

EVEREST Study

EVEREST: NPs and Congestion Scores

Relationships Between Discharge BNP and Outcomes

Therapies With Effects on BNP Levels

DOSE-AHF Study

Telemonitoring and Home-based Care

The Importance of Serial NP Measurements for Prognostication in Chronic HF

PROTECT Study Primary End Point: Total Cardiovascular Events

PROTECT Secondary End Points: HF Hospitalization and Rehospitalization

Guided Therapy Combined Analyses Suggest Benefit, All-Cause Mortality

The GUIDE-IT Trial

Home Testing

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)